관류 시스템 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of perfusion systems Market

The global perfusion systems market was valued at USD 5.45 billion in 2025 and is projected to grow from USD 5.97 billion in 2026 to USD 14.77 billion by 2034, registering a robust CAGR of 12.00% during the forecast period. North America dominated the global market with a 39.50% market share in 2025, supported by a high volume of cardiovascular surgeries, increasing organ transplantation procedures, and strong adoption of advanced perfusion technologies.

Perfusion systems are medical devices designed to temporarily replace or support the function of vital organs such as the heart and lungs during complex surgical procedures and organ transplantation. These systems maintain blood circulation and oxygen delivery while surgeons perform life-saving operations. Rising cases of cardiovascular diseases, chronic respiratory disorders, kidney failure, and organ transplantation are significantly driving demand for advanced perfusion technologies worldwide. Additionally, the growing elderly population and continuous technological innovations are expected to further accelerate market expansion through 2034.

The COVID-19 pandemic temporarily slowed market growth due to reduced organ donation and transplantation procedures, along with postponed elective surgeries. However, the market has recovered steadily with the resumption of transplant programs and increasing investments in advanced healthcare infrastructure.

Rising Adoption of Machine Perfusion Emerging as a Major Market Trend

One of the most significant trends shaping the perfusion systems market is the increasing preference for machine perfusion technologies over conventional organ preservation methods. Machine perfusion improves organ viability, reduces rejection rates, and extends preservation time before transplantation.

Healthcare organizations and government agencies across the U.S., Europe, Japan, and China are promoting hypothermic and normothermic machine perfusion techniques to improve transplant success rates. The increasing number of donation after circulatory death (DCD) organ donations has further encouraged the adoption of advanced perfusion systems. At the same time, manufacturers are investing heavily in next-generation perfusion devices for heart, lungs, kidneys, and liver preservation, expanding the clinical applications of these technologies.

Increasing Burden of Chronic Diseases Driving Market Growth

The growing prevalence of cardiovascular diseases, chronic kidney disease, respiratory illnesses, and organ failure remains one of the strongest growth drivers for the global perfusion systems market. Sedentary lifestyles, unhealthy diets, aging populations, and rising obesity rates continue to increase the number of patients requiring complex cardiovascular surgeries and organ transplantation.

Growing healthcare expenditure and expanding transplant infrastructure are encouraging hospitals to adopt technologically advanced perfusion systems that enhance surgical safety and improve patient outcomes. Furthermore, increasing research and development investments by leading medical device manufacturers are resulting in innovative products featuring enhanced monitoring capabilities, automation, and improved perfusion accuracy.

High Equipment Costs Continue to Challenge Market Expansion

Despite strong growth prospects, the high acquisition and maintenance costs associated with perfusion systems remain a major challenge, particularly in developing economies. Advanced heart-lung machines, ECMO systems, and organ perfusion devices require substantial capital investment, making them less affordable for smaller healthcare facilities.

In addition, transplantation procedures involve significant long-term treatment expenses, including immunosuppressive therapies, which may limit patient access in cost-sensitive markets. The absence of standardized protocols for perfusion monitoring and reporting also creates operational challenges that could slow wider adoption across emerging healthcare systems.

Cardiopulmonary Perfusion Systems Lead Product Segment

Based on product type, the cardiopulmonary perfusion systems segment is expected to dominate the market with a 76.57% share in 2026. Increasing numbers of cardiac surgeries, heart failure cases, lung transplantation procedures, and coronary bypass surgeries continue to support strong demand for these systems.

The isolated organ perfusion systems segment is projected to witness the fastest growth throughout the forecast period due to expanding research activities and growing adoption of advanced organ preservation technologies. Meanwhile, the ECMO segment is also expected to record steady growth as more hospitals establish specialized ECMO centers for critically ill patients.

Adult Patients and Hospitals Continue to Generate Strong Demand

By age group, adults are expected to account for 58.42% of the market in 2026, reflecting the rising prevalence of cardiovascular diseases and organ failure among the aging population. However, the pediatric segment is also expected to grow steadily due to increasing congenital heart disease cases requiring specialized surgical procedures.

Among end users, hospitals and ambulatory surgical centers (ASCs) are projected to hold the largest market share of 45.60% in 2026. These facilities perform the majority of organ transplantations and complex cardiac surgeries while increasingly investing in advanced perfusion technologies. Specialty clinics and research institutes are also expanding their adoption as clinical research and innovation continue to advance.

North America Maintains Market Leadership

North America remained the largest regional market, generating USD 2.16 billion in 2025 and projected to reach USD 2.37 billion in 2026. The region benefits from advanced healthcare infrastructure, high transplant volumes, strong reimbursement systems, and continuous product innovation. The U.S. market alone is expected to reach USD 2.20 billion by 2026.

Europe recorded USD 1.98 billion in 2025 and is projected to reach USD 2.16 billion in 2026, supported by increasing organ transplantation procedures and rising cases of chronic organ failure. Asia Pacific generated USD 0.84 billion in 2025 and is expected to reach USD 0.93 billion in 2026, driven by expanding healthcare infrastructure, aging populations, and increasing chronic disease prevalence. Latin America and the Middle East & Africa are also expected to witness healthy growth due to improving healthcare investments and rising awareness regarding organ transplantation.

Leading Companies Strengthen Competitive Position Through Innovation

The global perfusion systems market is moderately consolidated, with major companies continuously introducing technologically advanced products and expanding their global presence. Leading manufacturers include LivaNova PLC, Getinge, Medtronic, Terumo Corporation, XVIVO, and TransMedics. These companies are focusing on product approvals, research collaborations, distribution expansion, and innovative organ preservation technologies to strengthen their market position.

Recent industry developments include Terumo Corporation receiving U.S. FDA clearance for its CDI OneView Monitoring System in 2024, LivaNova launching the Essenz Heart-Lung Machine in the U.S., and continued investments by XVIVO in advanced heart preservation technologies.

Conclusion

The global perfusion systems market is expected to witness substantial growth between 2026 and 2034, driven by increasing cardiovascular surgeries, expanding organ transplantation programs, rising prevalence of chronic diseases, and rapid technological advancements in machine perfusion systems. Although high equipment costs remain a challenge in developing regions, continuous innovation, expanding healthcare infrastructure, and growing awareness regarding advanced transplant technologies are expected to support long-term market expansion. With increasing investments from leading manufacturers and healthcare providers, the perfusion systems market is well positioned to achieve sustained growth through 2034.

Segmentation By Product Type

• Cardiopulmonary Perfusion Systems
  • Oxygenation Systems
  • Heart-Lung Machines
  • Cooling and Heating Devices
  • Blood Parameter Monitoring Systems
  • Centrifugal Blood Pump Systems
  • Others
• Extracorporeal Membrane Oxygenation (ECMO)
• Isolated Organ Perfusion Systems

By Age Group

• Adults
• Pediatrics

By End User

• Hospitals & ASCs
• Specialty Clinics
• Others

By Region

• North America (By Product Type, By Age Group, By End User, By Country)
  • U.S.
  • Canada
• Europe (By Product Type, By Age Group, By End User, By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, By Age Group, By End User, By Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, By Age Group, By End User, By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, By Age Group, By End User, By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Cardiovascular Diseases - Key Countries, 2025
• 4.2. Number of Major Organ Transplantations, By Key Countries, 2025
• 4.3. Pricing Analysis, Key Products, Key Countries/Regions
• 4.4. New Product Launches, Key Players
• 4.5. Key Industry Developments - Mergers, Acquisitions & Partnerships
• 4.6. Impact of COVID-19 on the Market

5. Global Perfusion Systems Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Cardiopulmonary Perfusion Systems
    • 5.1.1.1. Oxygenation Systems
    • 5.1.1.2. Heart-lung Machines
    • 5.1.1.3. Cooling and Heating Devices
    • 5.1.1.4. Blood Parameter Monitoring Systems
    • 5.1.1.5. Centrifugal Blood Pump Systems
    • 5.1.1.6. Others
  • 5.1.2. Extracorporeal Membrane Oxygenation (ECMO)
  • 5.1.3. Isolated Organ Perfusion Systems
• 5.2. Market Analysis, Insights and Forecast - By Age Group
  • 5.2.1. Adults
  • 5.2.2. Pediatrics
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals & ASCs
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Perfusion Systems Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Cardiopulmonary Perfusion Systems
    • 6.1.1.1. Oxygenation Systems
    • 6.1.1.2. Heart-lung Machines
    • 6.1.1.3. Cooling and Heating Devices
    • 6.1.1.4. Blood Parameter Monitoring Systems
    • 6.1.1.5. Centrifugal Blood Pump Systems
    • 6.1.1.6. Others
  • 6.1.2. Extracorporeal Membrane Oxygenation (ECMO)
  • 6.1.3. Isolated Organ Perfusion Systems
• 6.2. Market Analysis, Insights and Forecast - By Age Group
  • 6.2.1. Adults
  • 6.2.2. Pediatrics
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals & ASCs
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Perfusion Systems Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Cardiopulmonary Perfusion Systems
    • 7.1.1.1. Oxygenation Systems
    • 7.1.1.2. Heart-lung Machines
    • 7.1.1.3. Cooling and Heating Devices
    • 7.1.1.4. Blood Parameter Monitoring Systems
    • 7.1.1.5. Centrifugal Blood Pump Systems
    • 7.1.1.6. Others
  • 7.1.2. Extracorporeal Membrane Oxygenation (ECMO)
  • 7.1.3. Isolated Organ Perfusion Systems
• 7.2. Market Analysis, Insights and Forecast - By Age Group
  • 7.2.1. Adults
  • 7.2.2. Pediatrics
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals & ASCs
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Perfusion Systems Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Cardiopulmonary Perfusion Systems
    • 8.1.1.1. Oxygenation Systems
    • 8.1.1.2. Heart-lung Machines
    • 8.1.1.3. Cooling and Heating Devices
    • 8.1.1.4. Blood Parameter Monitoring Systems
    • 8.1.1.5. Centrifugal Blood Pump Systems
    • 8.1.1.6. Others
  • 8.1.2. Extracorporeal Membrane Oxygenation (ECMO)
  • 8.1.3. Isolated Organ Perfusion Systems
• 8.2. Market Analysis, Insights and Forecast - By Age Group
  • 8.2.1. Adults
  • 8.2.2. Pediatrics
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals & ASCs
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Perfusion Systems Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Cardiopulmonary Perfusion Systems
    • 9.1.1.1. Oxygenation Systems
    • 9.1.1.2. Heart-lung Machines
    • 9.1.1.3. Cooling and Heating Devices
    • 9.1.1.4. Blood Parameter Monitoring Systems
    • 9.1.1.5. Centrifugal Blood Pump Systems
    • 9.1.1.6. Others
  • 9.1.2. Extracorporeal Membrane Oxygenation (ECMO)
  • 9.1.3. Isolated Organ Perfusion Systems
• 9.2. Market Analysis, Insights and Forecast - By Age Group
  • 9.2.1. Adults
  • 9.2.2. Pediatrics
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals & ASCs
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Perfusion Systems Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Cardiopulmonary Perfusion Systems
    • 10.1.1.1. Oxygenation Systems
    • 10.1.1.2. Heart-lung Machines
    • 10.1.1.3. Cooling and Heating Devices
    • 10.1.1.4. Blood Parameter Monitoring Systems
    • 10.1.1.5. Centrifugal Blood Pump Systems
    • 10.1.1.6. Others
  • 10.1.2. Extracorporeal Membrane Oxygenation (ECMO)
  • 10.1.3. Isolated Organ Perfusion Systems
• 10.2. Market Analysis, Insights and Forecast - By Age Group
  • 10.2.1. Adults
  • 10.2.2. Pediatrics
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals & ASCs
  • 10.3.2. Specialty Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Cardinal Health
    • 11.2.1.1. Overview
    • 11.2.1.2. Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Terumo Corporation
    • 11.2.2.1. Overview
    • 11.2.2.2. Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Medtronic
    • 11.2.3.1. Overview
    • 11.2.3.2. Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. NIPRO
    • 11.2.4.1. Overview
    • 11.2.4.2. Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. LivaNova PLC
    • 11.2.5.1. Overview
    • 11.2.5.2. Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Getinge
    • 11.2.6.1. Overview
    • 11.2.6.2. Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. XVIVO
    • 11.2.7.1. Overview
    • 11.2.7.2. Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. MicroPort Scientific Corporation
    • 11.2.8.1. Overview
    • 11.2.8.2. Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. TransMedics
    • 11.2.9.1. Overview
    • 11.2.9.2. Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. ECM Europe BV
    • 11.2.10.1. Overview
    • 11.2.10.2. Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)